Choking

T. ROWE PRICE 2022 MIDYEAR MARKET OUTLOOK: GLOBAL AND GEOPOLITICAL HEADWINDS LEAD FINANCIAL MARKETS TO INFLECTION POINT

Retrieved on: 
Wednesday, June 15, 2022
Fed, Wind, United States Treasury security, COVID-19, Bighorn sheep, All rights reserved, Environment, Person, T. Rowe Price, Research, Ideology of the Chinese Communist Party, LinkedIn, Pressure, Growth, Marketing, YouTube, Investment, Food, Twitter, Communist party, Choking, Instagram, Mark (given name), Income, Risk, Party, Security (finance), Financial adviser, Renewable energy, Bank, Milk, Drug, Financial services, Cryptocurrency, Asset management, Insurance, Chinese, Facebook

BALTIMORE, June 15, 2022 /PRNewswire/ -- T. Rowe Price, a global investment management firm and a leader in retirement services, has released its midyear market outlook for 2022. It includes insights from three of the firm's senior investment executives:

Key Points: 
  • The financial penalties imposed on Russia in response to the invasion could accelerate another longer-term transition toward a less centralized global financial system.
  • T. Rowe Price group of companies including T. Rowe Price Associates, Inc. and/or its affiliates receive revenue from T. Rowe Price investment products and services.
  • Under no circumstances should the material, in whole or in part, be copied or redistributed without consent from T. Rowe Price.
  • T. ROWE PRICE, INVEST WITH CONFIDENCE, and the Bighorn Sheep design are, collectively and/or apart, trademarks of T. Rowe Price Group, Inc.

200 Children Now Saved from Choking Death by LifeVac

Retrieved on: 
Tuesday, June 14, 2022
Heimlich, Child, Abdominal thrusts, MHRA, FDA, Choking, Family, Parent, Friends, Pain, Female, Airline

TAVERNIER, Fla., June 14, 2022 /PRNewswire/ -- LifeVac is pleased to announce that they have received word of the 200th child saved from suffocation during a choking emergency due to the effective implementation of the LifeVac airway clearance device. The choking emergency occurred in Tavernier, Florida on March 31, 2022.

Key Points: 
  • TAVERNIER, Fla., June 14, 2022 /PRNewswire/ --LifeVac is pleased to announce that they have received word of the 200th child saved from suffocation during a choking emergency due to the effective implementation of the LifeVac airway clearance device.
  • Upon realizing that her airway was compromised, her parents attempted the Heimlich maneuver along with back blows, both of which failed.
  • They then used the LifeVac which successfully dislodged the piece of orange after only two tries.
  • "I feel an amazing sense of gratitude," said Founder and inventor of the LifeVac, Arthur Lih.

Electrolux voluntarily recalls certain icemakers due to possible safety issue

Retrieved on: 
Thursday, June 2, 2022
Electrolux, AEG, Choking, Taste, CPSC, Frigidaire, Solution, Multimedia, Home appliance, Industrial design

The recall reason is an issue with the icemaker's level detector arm, which under certain circumstances, can potentially break and fall into the ice bucket, posing a choking hazard.

Key Points: 
  • The recall reason is an issue with the icemaker's level detector arm, which under certain circumstances, can potentially break and fall into the ice bucket, posing a choking hazard.
  • "Consumer safety is our top priority, and we take this matter very seriously," says Electrolux North America Product Safety Director Chad Strickland.
  • "We have decided to voluntarily recall these affected icemakers and sincerely apologize for any inconvenience this may have caused."
  • Fast Track recalls are initiated by firms who commit to work with CPSC to quickly announce the remedy to protect consumers.

ProSomnus® Presents Data Validating Proprietary FDA-cleared Oral Appliance Therapy Devices at 2022 American Academy of Dental Sleep Medicine Annual Meeting

Retrieved on: 
Friday, May 13, 2022
American Academy, Somnolence, Annual general meeting, Obstructive sleep apnea, Snoring, 2021 Essex County Council election, Patient, Poster, Digital Archives, Choking, Stroke, Continuous positive airway pressure, Â, SAN, Computer-aided design, AHI, Compliance, Heart failure, MOG, Jaw, REI, CPAP, H1, Entrepreneurship, GLOBE, MIP, MD, Hypertension, Sleep, Pharmaceutical industry, Health insurance

ProSomnus presented the data in three poster presentations at the 2022 American Academy of Dental Sleep Medicine (AADSM) Annual Meeting, held from May 13-15 in Dallas, Texas.

Key Points: 
  • ProSomnus presented the data in three poster presentations at the 2022 American Academy of Dental Sleep Medicine (AADSM) Annual Meeting, held from May 13-15 in Dallas, Texas.
  • These data presented at AADSM validate ProSomnuss oral appliance therapy devices in mild and moderate obstructive sleep apnea and, in particular, show great promise among patients with severe obstructive sleep apnea, said John E. Remmers, MD, Chief Scientist of ProSomnus.
  • The presented abstracts validating ProSomnuss oral appliance therapy devices include:
    An evaluation of data from two studies found ProSomnuss oral appliance therapy effective with most severe obstructive sleep apnea patients, suggesting that oral appliance therapy could be a suitable alternative to CPAP, especially when generated from digital intraoral scans using computer-aided design and manufacturing.
  • With more than 150,000 patients treated, ProSomnuss devices are the most prescribed oral appliance therapy in the U.S. To learn more, visit www.ProSomnus.com .

Middletown, N.Y. Custodian Crowned 2022 Cintas Custodian of the Year

Retrieved on: 
Thursday, May 12, 2022
Manufacturing, Other Manufacturing, Primary, Secondary, Training, Education, Online, Rubbermaid Commercial Products, Standard, Twitter, Newell, Environment, CMI, SR, Choking, Association, Health, Nasdaq, School, Professional, Fortune 500, Abdominal thrusts, Foodservice, ISSA, Industry, CTAS, Marketing, RCP, Student, Global Biorisk Advisory Council, Safety, Faculty, LinkedIn, Achievement, Total Chalaco, Interior design, Management, Facebook, Cintas

The winner of the 2022 Cintas Custodian of the Year contest is Lydell Henderson from Presidential Park Elementary School in Middletown, N.Y.!

Key Points: 
  • The winner of the 2022 Cintas Custodian of the Year contest is Lydell Henderson from Presidential Park Elementary School in Middletown, N.Y.!
  • After nearly 90,000 votes were cast, Cintas Corporation (Nasdaq: CTAS) confirmed Lydell Henderson is this years contest winner.
  • Mr. Henderson was honored by over 1,500 students and staff in a surprise ceremony at the school and will receive a $10,000 cash prize from Cintas.
  • School custodians often go above and beyond their regular tasks, including the time Mr. Henderson helped to prevent a student from choking.

Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

Retrieved on: 
Tuesday, May 10, 2022
Mortality, NASDAQ, Polyphagia, Orphan, Perforated ulcer, GLOBE, Intellectual disability, NDA, Medicine, Body composition, PWS, Food, Growth hormone, Research, Cardiovascular disease, Choking, Patient, Prader–Willi syndrome, Caregiver, Degenerative disease, Acquisition, FDA, Diabetes, Therapy, Obesity, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, New Drug Application, Diazoxide, Quality of life, Income, Achievement, Securities Exchange Act of 1934, Puberty, CMC, SEC, Behavioral Problems, PES, PAS, Pharmaceutical industry, Online gambling, EU

REDWOOD CITY, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three months ended March 31, 2022.

Key Points: 
  • REDWOOD CITY, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three months ended March 31, 2022.
  • First Quarter EndedMarch 31, 2022Financial Results
    Research and development expenses were$4.0 millionfor the quarter endedMarch 31, 2022, compared to$7.2 millionin the same period of 2021.
  • General and administrative expense was$2.6 millionfor the quarter endedMarch 31, 2022, compared to$3.0 millionin the same period of 2021.
  • As ofMarch 31, 2022, Soleno had cash and cash equivalents of approximately$29.0 million, compared to$21.3 millionas ofDecember 31, 2021.

Plaquemine Woman Hospitalized due to Chlorine Gas Leak Files First Injury Lawsuit

Retrieved on: 
Wednesday, May 4, 2022
Dow Chemical Company, District court, Pulmonary edema, Local, Safety, Choking, Spriggs, Skin, Chlorine, Baton Rouge, Louisiana, Nose, Sensation

PLAQUEMINE, La., May 4, 2022 /PRNewswire/ -- An Iberville Parish resident who was hospitalized with severe chemical exposure reactions has filed the first injury lawsuit relating to a chlorine gas leak on April 18, 2022. The lawsuit is against the owners and operators of the Olin Chlor Alkali plant at the Dow Chemical facility in Plaquemine, located 15 miles south of downtown Baton Rouge.  

Key Points: 
  • PLAQUEMINE, La., May 4, 2022 /PRNewswire/ -- An Iberville Parish resident who was hospitalized with severe chemical exposure reactions has filed the first injury lawsuit relating to a chlorine gas leak on April 18, 2022.
  • Local officials later issued shelter-in-place orders to residents after the leak was reported, but Ms. Spriggs had already been exposed, according to the lawsuit.
  • In addition to Ms. Spriggs, more than 35 other nearby residents were reportedly hospitalized due to the leak.
  • The Potts Law Firm already represents more than 100 Plaquemine residents injured due to chemical exposure from the incident.

CYBEX INITIATES VOLUNTARY SAFETY RECALL OF SELECT U.S. VERSIONS OF THE SIRONA M CONVERTIBLE CAR SEATS

Retrieved on: 
Wednesday, April 20, 2022
Injury, Caregiver, Sale, Safety, Sirona, Choking, Infant, Crashworthiness, Multimedia, View, Toy, Baggage, Online shopping

CANTON, Mass., April 20, 2022 /PRNewswire/ -- CYBEX, a leading manufacturer and marketer of infant and juvenile products, today initiated a voluntary safety recall of select U.S. versions of the Sirona M convertible car seats due to some children accessing and picking off the foam from the headrest through a small opening in the headrest cover set. The foam pieces are very small, are generally spherical with no sharp edges, and are non-toxic. However, these very small foam pieces could be a choking hazard. There have been no reports to CYBEX of injuries to children in connection with the foam from the U.S. Sirona M. The car seat continues to meet all requirements for crashworthiness. The affected U.S. versions of the Sirona M car seat can continue to be used to transport children safely.

Key Points: 
  • There have been no reports to CYBEX of injuries to children in connection with the foam from the U.S. Sirona M. The car seat continues to meet all requirements for crashworthiness.
  • The affected U.S. versions of the Sirona M car seat can continue to be used to transport children safely.
  • Versions of Sirona M Convertible Car Seats
    This voluntary U.S. recall involves the Sirona M seats built before September 1, 2018 with Model Numbers 518000385, 518000387, 518002145, 518002145, 518002149, 518002151, 518002153, and 519000211.
  • Importantly, the U.S. Sirona M car seat affected by this recall meets all safety requirements, so it may be used while consumers wait for the product improvement kit.

Journal of Clinical Sleep Medicine Publication Shows Efficacy of ProSomnus® Precision Oral Appliance Therapy Devices in Treating Obstructive Sleep Apnea

Retrieved on: 
Tuesday, April 5, 2022
CPAP, Journal, Somnolence, Obstructive sleep apnea, Journal of Clinical Sleep Medicine, Compliance, Continuous positive airway pressure, Sleep, Patient, Hypertension, CEO, Mandible, MD, Stroke, Choking, GLOBE, SAN, OAT, Heart failure, Pharmaceutical industry

SAN FRANCISCO, April 05, 2022 (GLOBE NEWSWIRE) -- ProSomnus Sleep Technologies (“ProSomnus”), the leader in patient-preferred medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced the results of a peer-reviewed study published by the Journal of Clinical Sleep Medicine (JCSM), which found that ProSomnus’s precision Oral Appliance Therapy (OAT) devices successfully treated most patients’ OSA.

Key Points: 
  • SAN FRANCISCO, April 05, 2022 (GLOBE NEWSWIRE) -- ProSomnus Sleep Technologies (ProSomnus), the leader in patient-preferred medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced the results of a peer-reviewed study published by the Journal of Clinical Sleep Medicine (JCSM), which found that ProSomnuss precision Oral Appliance Therapy (OAT) devices successfully treated most patients OSA.
  • The ProSomnus precision OAT device uses proprietary technologies to replicate the bite position provided by the MATRx plus test.
  • ProSomnus is the first manufacturer of precision, mass-customized Oral Appliance Therapy (OAT) devices to treat Obstructive Sleep Apnea, which affects over 74 million Americans and is associated with serious comorbidities, including heart failure, stroke, hypertension, morbid obesity and type 2 diabetes.
  • With more than 135,000 patients treated, ProSomnuss devices are the most prescribed OATs in the U.S. To learn more, visit www.ProSomnus.com .

Soleno Therapeutics Announces Closing of Approximately $15 Million Underwritten Public Offering

Retrieved on: 
Friday, April 1, 2022
Therapy, Obesity, Oppenheimer, Orphan, Body composition, NASDAQ, Degenerative disease, Sale, Form, Attention, Mortality, Caregiver, Public expenditure, Tablet, Research, SEC, Intellectual disability, Polyphagia, Cardiovascular disease, Telephone, Puberty, Medicine, Diazoxide, Behavioral Problems, Growth hormone, Prospectus, Quality of life, Diabetes, PWS, Perforated ulcer, Choking, Securities Exchange Act of 1934, Prader–Willi syndrome, GLOBE, NDA, FDA, Patient, SEC filing, Security (finance), Pharmaceutical industry, EU

Oppenheimer & Co. Inc.acted as the sole book-running manager for the offering.Laidlaw & Company (UK) Ltd. acted as co-manager for the offering.

Key Points: 
  • Oppenheimer & Co. Inc.acted as the sole book-running manager for the offering.Laidlaw & Company (UK) Ltd. acted as co-manager for the offering.
  • The offering was conducted pursuant to the Companys shelf registration statement on Form S-3 (File No.
  • Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases.
  • Soleno conceived of and established extensive patent protection on the therapeutic use of diazoxide and DCCR in patients with PWS.